Evidence map›Paper›PMID 37914171›Full record

ArticleBMJ case reports2023

Pembrolizumab-induced immune-related sclerosing cholangitis.

Yuchen Li, Lori Stewart, Shangguo Tang, Elaine McWhirter

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Yuchen LiMedical Oncology, Juravinski Cancer Centre, Hamilton, Ontario, Canada.
Lori StewartDiagnostic Imaging, Juravinski Hospital, Hamilton, Ontario, Canada.
Shangguo TangPathology, McMaster University Medical Centre, Hamilton, Ontario, Canada.
Elaine McWhirterMedical Oncology, Juravinski Cancer Centre, Hamilton, Ontario, Canada emcwhirt@hhsc.ca.
Juravinski Cancer Centre · CAJuravinski Hospital · CAMcMaster University Medical Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy is increasingly used to treat various types of cancer; however, it can often result in immune-related adverse events (irAEs). Immune-related sclerosing cholangitis (irSC) is a rare type of hepatic irAE that has been described only in a few cases, and much remains unknown about its optimal treatment. In this report, we describe the case of a man in his 70s who was diagnosed with metastatic melanoma and treated with pembrolizumab. He experienced multiple irAEs, including irSC, which did not respond to initial prednisone treatment (2 mg/kg daily dosing). However, subsequent treatment with ursodeoxycholic acid (UDCA) resulted in complete resolution of symptoms and normalisation of laboratory and radiographic abnormalities related to irSC. Our case suggests that steroids, which are traditionally used to treat irAEs, may be ineffective for irSC and that UDCA may be a better alternative. Clinicians should be aware of this rare irAE.

Indexed as

Cholangitis, SclerosingMelanomaAntibodies, Monoclonal, HumanizedHumansMaleUrsodeoxycholic AcidAntibodies, Monoclonal, HumanizedpembrolizumabUrsodeoxycholic AcidCancer - see OncologyImmunologyMedical managementSkin cancer

Identifiers

PMID37914171
PMCPMC10626897
OpenAlexW4388142123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.